Category Archives: Mesenchymal Stem Cells

Pastor Chui Depending on Source, Stem Cells Can Kill or Heal This is a 13-minute sermon from science. It describes why adult stem cells heal and embryonic stem cells destroy life in them. Adult stem cells have more pro... By: Christopher Chui … Continue reading →

Multiple Sclerosis Treatment Stem Cells Multiple Sclerosis Treatment options using Stem Cells Our doctors have successfully performed the CCSVI procedure on hundreds of MS patients. To find out mor... By: Jason Ratzlaff … Continue reading →

NEW YORK and MELBOURNE, Australia, June 4, 2013 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today announced that it has been granted a key patent by the Japanese Patent Office. Japanese patent number 5265190 provides Mesoblast with exclusive commercial rights in Japan through to September 2025 to all compositions-of-matter and uses of its Mesenchymal Precursor Cell (MPC) technology platform, irrespective of the MPC tissue source, including bone marrow, adipose, placenta, umbilical cord and dental pulp. The granting of the Japanese patent follows the recent extension of compositions-of-matter patents by the United States Patent and Trade Mark Office to March 2029, and two key patents from the State Intellectual Property Office of the People's Republic of China that provide commercial rights and protection through to 2025. The Japanese patent underpins Mesoblast's corporate strategy to protect intellectual property covering its lead clinical products, to safeguard its manufacturing processes and knowledge, and to extend the commercial reach of its proprietary technologies in the world's major markets for regenerative medicines. About Mesoblast Mesoblast Limited is a world leader in the development of biologic products for the broad field of regenerative medicine. The Company's technologies include its proprietary Mesenchymal Precursor Cell (MPC) … Continue reading →

Public release date: 4-Jun-2013 [ | E-mail | Share ] Contact: Evan Lerner elerner@upenn.edu 215-573-6604 University of Pennsylvania Cartilage injuries are difficult to repair. Current surgical options generally involve taking a piece from another part of the injured joint and patching over the damaged area, but this approach involves damaging healthy cartilage, and a person's cartilage may still deteriorate with age. Bioengineers are interested in finding innovative ways to grow new cartilage from a patient's own stem cells, and, thanks to a new study from the University of Pennsylvania, such a treatment is a step closer to reality. The research was conducted by associate professor Jason Burdick of the Department of Bioengineering in the School of Engineering and Applied Science and associate professor Robert Mauck of the Department of Orthopaedic Surgery in Penn's Perelman School of Medicine. Liming Bian and Murat Guvendiren, members of Burdick's lab, also took part. It was published in the Proceedings of the National Academy of Sciences. "The broad picture," Burdick said, "is trying to develop new therapies to replace cartilage tissue, starting with focal defects things like sports injuries and then hopefully moving toward surface replacement for cartilage degradation that comes with aging. Here, we're … Continue reading →

June 4, 2013 Cartilage injuries are difficult to repair. Current surgical options generally involve taking a piece from another part of the injured joint and patching over the damaged area, but this approach involves damaging healthy cartilage, and a person's cartilage may still deteriorate with age. Bioengineers are interested in finding innovative ways to grow new cartilage from a patient's own stem cells, and, thanks to a new study from the University of Pennsylvania, such a treatment is a step closer to reality. The research was conducted by associate professor Jason Burdick of the Department of Bioengineering in the School of Engineering and Applied Science and associate professor Robert Mauck of the Department of Orthopaedic Surgery in Penn's Perelman School of Medicine. Liming Bian and Murat Guvendiren, members of Burdick's lab, also took part. It was published in the Proceedings of the National Academy of Sciences. "The broad picture," Burdick said, "is trying to develop new therapies to replace cartilage tissue, starting with focal defects -- things like sports injuries -- and then hopefully moving toward surface replacement for cartilage degradation that comes with aging. Here, we're trying to figure out the right environment for adult stem cells to produce … Continue reading →

Washington, June 3 (ANI): Indian origin researchers at North Dakota State University, Fargo, are making strides in tissue engineering - designing scaffolds that may lead to ways to regenerate bone. The research of Dr. Kalpana Katti, Dr. Dinesh Katti and graduate student Avinash Ambre includes a novel method that uses nanosized clays to make scaffolds to mineralize bone minerals such as hydroxyapatite. The NDSU research team's 3-D mesh scaffold is comprised of degradable materials that are compatible to human tissue. Over time, the cells generate bone and the scaffold deteriorates. As indicated in the NDSU team's published scientific research from 2008 to 2013, the nanoclays enhance the mechanical properties of the scaffold by enabling scaffold to bear load while bone generates. An interesting finding by the Katti group has shown that the nanoclays also impart useful biological properties to the scaffold. "The biomineralized nanoclays also impart osteogenic or bone-forming abilities to the scaffold to enable birth of bone," said Dr. Kalpana Katti, Distinguished Professor of civil engineering at NDSU. "Although it would have been exciting to say that this finding had a 'Eureka moment,' this discovery was a methodical exploration of simulations and modeling, indicating that amino acid modified nanoclays … Continue reading →

HALO-96 PQR: How to Measure Potency of Hematopoietic Mesenchymal Stem Cell Products This last technical guide video on potency demonstrates how potency is measured using using the HALO-96 PQR assay kit using umbilical cord blood stem cells a... By: HemoGenix … Continue reading →

CLEVELAND, June 3, 2013 /PRNewswire/ --Arteriocyte, Inc., a leading biotechnology company that is focused on developing and enabling commercial stem cell based therapies announced the launch of Compass Biomedical, the commercial tools division of Arteriocyte that supplies novel cell culturing products and technologies for translational research. As part of the Arteriocyte family, Compass Biomedical has access to the pipeline of cutting edge research from Arteriocyte's research and development team, as well as collaboration partnerships with leading research institutions making Compass Biomedical an ideal choice to help accelerate the transition from basic research to clinical application. Compass Biomedical already supplies 3 product lines: 1) NANEX Cell Culture and Expansion Kit; 2) Adhere-34 Cell Culture and Expansion Bag; and 3) PLUS Cell Culture Supplement. Compass Biomedical's core products are based upon the NANEX biofunctional nanofiber-based technology, that was designed to partially mimic key features of human bone marrow enabling rapid ex vivo cell growth and expansion while maintaining the stem cell's properties. It is an ideal solution for rapidly culturing hematopoietic stem and progenitor cells (HSC/HPCs) for basic research, therapeutics, drug discovery, and screening. These expanded cells have been used to grow new blood cells (including red blood cells and platelets) and … Continue reading →

May 30, 2013 Weak bones, broken bones, damaged bones, arthritic bones. Whether damaged by injury, disease or age, your body can't create new bone, but maybe science can. Researchers at North Dakota State University, Fargo, are making strides in tissue engineering, designing scaffolds that may lead to ways to regenerate bone. Published in the Journal of Biomedical Materials Research Part A, the research of Dr. Kalpana Katti, Dr. Dinesh Katti and graduate student Avinash Ambre includes a novel method that uses nanosized clays to make scaffolds to mineralize bone minerals such as hydroxyapatite. The NDSU research team's 3-D mesh scaffold is composed of degradable materials that are compatible to human tissue. Over time, the cells generate bone and the scaffold deteriorates. As indicated in the NDSU team's published scientific research from 2008 to 2013, the nanoclays enhance the mechanical properties of the scaffold by enabling scaffold to bear load while bone generates. An interesting finding by the Katti group has shown that the nanoclays also impart useful biological properties to the scaffold. "The biomineralized nanoclays also impart osteogenic or bone-forming abilities to the scaffold to enable birth of bone," said Dr. Kalpana Katti, Distinguished Professor of civil engineering at NDSU. … Continue reading →

COLUMBIA, Md.--(BUSINESS WIRE)-- Osiris Therapeutics, Inc. (OSIR), the leading stem cell company focused on developing and marketing products to treat medical conditions in inflammatory, cardiovascular, orthopedic and wound healing markets, announced today that C. Randal Mills, Ph.D., President and Chief Executive Officer, is scheduled to present at the Jefferies 2013 Global Healthcare Conference on Monday, June 3, 2013 at 4:00 p.m. ET in New York City. A live webcast of the presentation may be accessed through the Investors page of the Companys website at http://www.Osiris.com. A replay of the webcast will be available for one week following the conference. About Osiris Therapeutics Osiris Therapeutics, Inc., is the leading stem cell company, having developed the worlds first approved stem cell drug, Prochymal. Osiris currently markets Grafix and Ovation for wound and tissue repair, and CartiformTM for cartilage repair. Osiris is a fully integrated company with capabilities in research, development, manufacturing and distribution of cell therapy products. Osiris has developed an extensive intellectual property portfolio to protect the company's technology, including 50 U.S. and 156 foreign patents. Osiris, Prochymal, Chondrogen, Grafix and Ovation are registered trademarks of Osiris Therapeutics, Inc. More information can be found on the company's website, http://www.Osiris.com. (OSIR-G) Forward-Looking … Continue reading →